integrin inhibitor Search Results


aβ1-11  (Bachem)
90
Bachem aβ1-11
Aβ1 11, supplied by Bachem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/aβ1-11/product/Bachem
Average 90 stars, based on 1 article reviews
aβ1-11 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
cyclic peptide inhibitor of integrin α4β1 (azide modified peptide: mephe-leu-asp-val-aib-lys)  (InnoPep Inc)
90
InnoPep Inc cyclic peptide inhibitor of integrin α4β1 (azide modified peptide: mephe-leu-asp-val-aib-lys)
(A) Images of RBCs/mo-DCs aggregates captured by Keyence fluorescence microscope. RBCs and mo-DCs were pre-labeled with WGA-555 and Hoechst dye, respectively. Top panels show medium control; middle panels show LPS treated RBCs group (LPS 50 μg/ml for 24 h); bottom panels show the RBCs/mo-DCs group with RBC pretreated with 10 µM of the cyclic peptide inhibitor of <t>integrin</t> <t>α4β1.</t> White arrows pointed RBCs/mo-DCs aggregates. (B) The imaging strategy to distinguish cell aggregation with the corresponding three cell types in cell suspension. RBCs, mo-DCs, and HLMVEC were pre-labeled with WGA-555, Hoechst dye and WGA-488 respectively. Accordingly, aggregates were defined as RBCs/mo-DCs (white arrows), RBCs/HLMEC (yellow arrows), and RBCs/mo-DCs/HLMEC (pink arrows). (C) Quantification of cell aggregation calculated by imaging analysis software (left two panels). Several controls were used to access the ability of cell aggregation as indicated. Flow cytometric analysis of the integrin β1 expression on RBCs (middle panel). Integrin β1 on RBCs treated by LPS increased significantly compared to untreated control (graph bar panel, right side of flow cytometry picture). The α4β1 peptide inhibitor (10 µM) or Natalizmab (10 μg/ml) blocked cell-cell aggregation of RBCs/mo-DCs in a concentration-dependent manner while peptide control or Methylprednisolone alone had no effect on cell aggregation (Bottom right panel). All data were representative of mean ± SD, with at least three biological replicates. * p < 0.05, *** p < 0.001.
Cyclic Peptide Inhibitor Of Integrin α4β1 (Azide Modified Peptide: Mephe Leu Asp Val Aib Lys), supplied by InnoPep Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cyclic peptide inhibitor of integrin α4β1 (azide modified peptide: mephe-leu-asp-val-aib-lys)/product/InnoPep Inc
Average 90 stars, based on 1 article reviews
cyclic peptide inhibitor of integrin α4β1 (azide modified peptide: mephe-leu-asp-val-aib-lys) - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
integrin α v inhibitor cyclo-(arg-gly-asp- d -phe-val)  (Bachem)
90
Bachem integrin α v inhibitor cyclo-(arg-gly-asp- d -phe-val)
(A) Images of RBCs/mo-DCs aggregates captured by Keyence fluorescence microscope. RBCs and mo-DCs were pre-labeled with WGA-555 and Hoechst dye, respectively. Top panels show medium control; middle panels show LPS treated RBCs group (LPS 50 μg/ml for 24 h); bottom panels show the RBCs/mo-DCs group with RBC pretreated with 10 µM of the cyclic peptide inhibitor of <t>integrin</t> <t>α4β1.</t> White arrows pointed RBCs/mo-DCs aggregates. (B) The imaging strategy to distinguish cell aggregation with the corresponding three cell types in cell suspension. RBCs, mo-DCs, and HLMVEC were pre-labeled with WGA-555, Hoechst dye and WGA-488 respectively. Accordingly, aggregates were defined as RBCs/mo-DCs (white arrows), RBCs/HLMEC (yellow arrows), and RBCs/mo-DCs/HLMEC (pink arrows). (C) Quantification of cell aggregation calculated by imaging analysis software (left two panels). Several controls were used to access the ability of cell aggregation as indicated. Flow cytometric analysis of the integrin β1 expression on RBCs (middle panel). Integrin β1 on RBCs treated by LPS increased significantly compared to untreated control (graph bar panel, right side of flow cytometry picture). The α4β1 peptide inhibitor (10 µM) or Natalizmab (10 μg/ml) blocked cell-cell aggregation of RBCs/mo-DCs in a concentration-dependent manner while peptide control or Methylprednisolone alone had no effect on cell aggregation (Bottom right panel). All data were representative of mean ± SD, with at least three biological replicates. * p < 0.05, *** p < 0.001.
Integrin α V Inhibitor Cyclo (Arg Gly Asp D Phe Val), supplied by Bachem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/integrin α v inhibitor cyclo-(arg-gly-asp- d -phe-val)/product/Bachem
Average 90 stars, based on 1 article reviews
integrin α v inhibitor cyclo-(arg-gly-asp- d -phe-val) - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
rgd motive-containing integrin inhibitor peptide [cyclo(arggly-asp-d-phe-val)] 182015  (Merck KGaA)
90
Merck KGaA rgd motive-containing integrin inhibitor peptide [cyclo(arggly-asp-d-phe-val)] 182015
(A) Images of RBCs/mo-DCs aggregates captured by Keyence fluorescence microscope. RBCs and mo-DCs were pre-labeled with WGA-555 and Hoechst dye, respectively. Top panels show medium control; middle panels show LPS treated RBCs group (LPS 50 μg/ml for 24 h); bottom panels show the RBCs/mo-DCs group with RBC pretreated with 10 µM of the cyclic peptide inhibitor of <t>integrin</t> <t>α4β1.</t> White arrows pointed RBCs/mo-DCs aggregates. (B) The imaging strategy to distinguish cell aggregation with the corresponding three cell types in cell suspension. RBCs, mo-DCs, and HLMVEC were pre-labeled with WGA-555, Hoechst dye and WGA-488 respectively. Accordingly, aggregates were defined as RBCs/mo-DCs (white arrows), RBCs/HLMEC (yellow arrows), and RBCs/mo-DCs/HLMEC (pink arrows). (C) Quantification of cell aggregation calculated by imaging analysis software (left two panels). Several controls were used to access the ability of cell aggregation as indicated. Flow cytometric analysis of the integrin β1 expression on RBCs (middle panel). Integrin β1 on RBCs treated by LPS increased significantly compared to untreated control (graph bar panel, right side of flow cytometry picture). The α4β1 peptide inhibitor (10 µM) or Natalizmab (10 μg/ml) blocked cell-cell aggregation of RBCs/mo-DCs in a concentration-dependent manner while peptide control or Methylprednisolone alone had no effect on cell aggregation (Bottom right panel). All data were representative of mean ± SD, with at least three biological replicates. * p < 0.05, *** p < 0.001.
Rgd Motive Containing Integrin Inhibitor Peptide [Cyclo(arggly Asp D Phe Val)] 182015, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rgd motive-containing integrin inhibitor peptide [cyclo(arggly-asp-d-phe-val)] 182015/product/Merck KGaA
Average 90 stars, based on 1 article reviews
rgd motive-containing integrin inhibitor peptide [cyclo(arggly-asp-d-phe-val)] 182015 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
amphoteric cyclization reagents  (Encycle Therapeutics)
90
Encycle Therapeutics amphoteric cyclization reagents
(A) Images of RBCs/mo-DCs aggregates captured by Keyence fluorescence microscope. RBCs and mo-DCs were pre-labeled with WGA-555 and Hoechst dye, respectively. Top panels show medium control; middle panels show LPS treated RBCs group (LPS 50 μg/ml for 24 h); bottom panels show the RBCs/mo-DCs group with RBC pretreated with 10 µM of the cyclic peptide inhibitor of <t>integrin</t> <t>α4β1.</t> White arrows pointed RBCs/mo-DCs aggregates. (B) The imaging strategy to distinguish cell aggregation with the corresponding three cell types in cell suspension. RBCs, mo-DCs, and HLMVEC were pre-labeled with WGA-555, Hoechst dye and WGA-488 respectively. Accordingly, aggregates were defined as RBCs/mo-DCs (white arrows), RBCs/HLMEC (yellow arrows), and RBCs/mo-DCs/HLMEC (pink arrows). (C) Quantification of cell aggregation calculated by imaging analysis software (left two panels). Several controls were used to access the ability of cell aggregation as indicated. Flow cytometric analysis of the integrin β1 expression on RBCs (middle panel). Integrin β1 on RBCs treated by LPS increased significantly compared to untreated control (graph bar panel, right side of flow cytometry picture). The α4β1 peptide inhibitor (10 µM) or Natalizmab (10 μg/ml) blocked cell-cell aggregation of RBCs/mo-DCs in a concentration-dependent manner while peptide control or Methylprednisolone alone had no effect on cell aggregation (Bottom right panel). All data were representative of mean ± SD, with at least three biological replicates. * p < 0.05, *** p < 0.001.
Amphoteric Cyclization Reagents, supplied by Encycle Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/amphoteric cyclization reagents/product/Encycle Therapeutics
Average 90 stars, based on 1 article reviews
amphoteric cyclization reagents - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
αv-integrin inhibitor crgdfv  (Bachem)
90
Bachem αv-integrin inhibitor crgdfv
(A) Images of RBCs/mo-DCs aggregates captured by Keyence fluorescence microscope. RBCs and mo-DCs were pre-labeled with WGA-555 and Hoechst dye, respectively. Top panels show medium control; middle panels show LPS treated RBCs group (LPS 50 μg/ml for 24 h); bottom panels show the RBCs/mo-DCs group with RBC pretreated with 10 µM of the cyclic peptide inhibitor of <t>integrin</t> <t>α4β1.</t> White arrows pointed RBCs/mo-DCs aggregates. (B) The imaging strategy to distinguish cell aggregation with the corresponding three cell types in cell suspension. RBCs, mo-DCs, and HLMVEC were pre-labeled with WGA-555, Hoechst dye and WGA-488 respectively. Accordingly, aggregates were defined as RBCs/mo-DCs (white arrows), RBCs/HLMEC (yellow arrows), and RBCs/mo-DCs/HLMEC (pink arrows). (C) Quantification of cell aggregation calculated by imaging analysis software (left two panels). Several controls were used to access the ability of cell aggregation as indicated. Flow cytometric analysis of the integrin β1 expression on RBCs (middle panel). Integrin β1 on RBCs treated by LPS increased significantly compared to untreated control (graph bar panel, right side of flow cytometry picture). The α4β1 peptide inhibitor (10 µM) or Natalizmab (10 μg/ml) blocked cell-cell aggregation of RBCs/mo-DCs in a concentration-dependent manner while peptide control or Methylprednisolone alone had no effect on cell aggregation (Bottom right panel). All data were representative of mean ± SD, with at least three biological replicates. * p < 0.05, *** p < 0.001.
αv Integrin Inhibitor Crgdfv, supplied by Bachem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/αv-integrin inhibitor crgdfv/product/Bachem
Average 90 stars, based on 1 article reviews
αv-integrin inhibitor crgdfv - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
eptifibatide, a αiibβ3 integrin inhibitor (integrilin®)  (Schering-Plough corporation)
90
Schering-Plough corporation eptifibatide, a αiibβ3 integrin inhibitor (integrilin®)
(A) Images of RBCs/mo-DCs aggregates captured by Keyence fluorescence microscope. RBCs and mo-DCs were pre-labeled with WGA-555 and Hoechst dye, respectively. Top panels show medium control; middle panels show LPS treated RBCs group (LPS 50 μg/ml for 24 h); bottom panels show the RBCs/mo-DCs group with RBC pretreated with 10 µM of the cyclic peptide inhibitor of <t>integrin</t> <t>α4β1.</t> White arrows pointed RBCs/mo-DCs aggregates. (B) The imaging strategy to distinguish cell aggregation with the corresponding three cell types in cell suspension. RBCs, mo-DCs, and HLMVEC were pre-labeled with WGA-555, Hoechst dye and WGA-488 respectively. Accordingly, aggregates were defined as RBCs/mo-DCs (white arrows), RBCs/HLMEC (yellow arrows), and RBCs/mo-DCs/HLMEC (pink arrows). (C) Quantification of cell aggregation calculated by imaging analysis software (left two panels). Several controls were used to access the ability of cell aggregation as indicated. Flow cytometric analysis of the integrin β1 expression on RBCs (middle panel). Integrin β1 on RBCs treated by LPS increased significantly compared to untreated control (graph bar panel, right side of flow cytometry picture). The α4β1 peptide inhibitor (10 µM) or Natalizmab (10 μg/ml) blocked cell-cell aggregation of RBCs/mo-DCs in a concentration-dependent manner while peptide control or Methylprednisolone alone had no effect on cell aggregation (Bottom right panel). All data were representative of mean ± SD, with at least three biological replicates. * p < 0.05, *** p < 0.001.
Eptifibatide, A αiibβ3 Integrin Inhibitor (Integrilin®), supplied by Schering-Plough corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/eptifibatide, a αiibβ3 integrin inhibitor (integrilin®)/product/Schering-Plough corporation
Average 90 stars, based on 1 article reviews
eptifibatide, a αiibβ3 integrin inhibitor (integrilin®) - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
integrin inhibitor, small molecule clt-28643  (Clanotech)
90
Clanotech integrin inhibitor, small molecule clt-28643
(A) Images of RBCs/mo-DCs aggregates captured by Keyence fluorescence microscope. RBCs and mo-DCs were pre-labeled with WGA-555 and Hoechst dye, respectively. Top panels show medium control; middle panels show LPS treated RBCs group (LPS 50 μg/ml for 24 h); bottom panels show the RBCs/mo-DCs group with RBC pretreated with 10 µM of the cyclic peptide inhibitor of <t>integrin</t> <t>α4β1.</t> White arrows pointed RBCs/mo-DCs aggregates. (B) The imaging strategy to distinguish cell aggregation with the corresponding three cell types in cell suspension. RBCs, mo-DCs, and HLMVEC were pre-labeled with WGA-555, Hoechst dye and WGA-488 respectively. Accordingly, aggregates were defined as RBCs/mo-DCs (white arrows), RBCs/HLMEC (yellow arrows), and RBCs/mo-DCs/HLMEC (pink arrows). (C) Quantification of cell aggregation calculated by imaging analysis software (left two panels). Several controls were used to access the ability of cell aggregation as indicated. Flow cytometric analysis of the integrin β1 expression on RBCs (middle panel). Integrin β1 on RBCs treated by LPS increased significantly compared to untreated control (graph bar panel, right side of flow cytometry picture). The α4β1 peptide inhibitor (10 µM) or Natalizmab (10 μg/ml) blocked cell-cell aggregation of RBCs/mo-DCs in a concentration-dependent manner while peptide control or Methylprednisolone alone had no effect on cell aggregation (Bottom right panel). All data were representative of mean ± SD, with at least three biological replicates. * p < 0.05, *** p < 0.001.
Integrin Inhibitor, Small Molecule Clt 28643, supplied by Clanotech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/integrin inhibitor, small molecule clt-28643/product/Clanotech
Average 90 stars, based on 1 article reviews
integrin inhibitor, small molecule clt-28643 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
integrin inhibitors  (Merck KGaA)
90
Merck KGaA integrin inhibitors
(A) Images of RBCs/mo-DCs aggregates captured by Keyence fluorescence microscope. RBCs and mo-DCs were pre-labeled with WGA-555 and Hoechst dye, respectively. Top panels show medium control; middle panels show LPS treated RBCs group (LPS 50 μg/ml for 24 h); bottom panels show the RBCs/mo-DCs group with RBC pretreated with 10 µM of the cyclic peptide inhibitor of <t>integrin</t> <t>α4β1.</t> White arrows pointed RBCs/mo-DCs aggregates. (B) The imaging strategy to distinguish cell aggregation with the corresponding three cell types in cell suspension. RBCs, mo-DCs, and HLMVEC were pre-labeled with WGA-555, Hoechst dye and WGA-488 respectively. Accordingly, aggregates were defined as RBCs/mo-DCs (white arrows), RBCs/HLMEC (yellow arrows), and RBCs/mo-DCs/HLMEC (pink arrows). (C) Quantification of cell aggregation calculated by imaging analysis software (left two panels). Several controls were used to access the ability of cell aggregation as indicated. Flow cytometric analysis of the integrin β1 expression on RBCs (middle panel). Integrin β1 on RBCs treated by LPS increased significantly compared to untreated control (graph bar panel, right side of flow cytometry picture). The α4β1 peptide inhibitor (10 µM) or Natalizmab (10 μg/ml) blocked cell-cell aggregation of RBCs/mo-DCs in a concentration-dependent manner while peptide control or Methylprednisolone alone had no effect on cell aggregation (Bottom right panel). All data were representative of mean ± SD, with at least three biological replicates. * p < 0.05, *** p < 0.001.
Integrin Inhibitors, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/integrin inhibitors/product/Merck KGaA
Average 90 stars, based on 1 article reviews
integrin inhibitors - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
α2β1 integrin inhibitors  (ShangPharma corp)
90
ShangPharma corp α2β1 integrin inhibitors
(A) Images of RBCs/mo-DCs aggregates captured by Keyence fluorescence microscope. RBCs and mo-DCs were pre-labeled with WGA-555 and Hoechst dye, respectively. Top panels show medium control; middle panels show LPS treated RBCs group (LPS 50 μg/ml for 24 h); bottom panels show the RBCs/mo-DCs group with RBC pretreated with 10 µM of the cyclic peptide inhibitor of <t>integrin</t> <t>α4β1.</t> White arrows pointed RBCs/mo-DCs aggregates. (B) The imaging strategy to distinguish cell aggregation with the corresponding three cell types in cell suspension. RBCs, mo-DCs, and HLMVEC were pre-labeled with WGA-555, Hoechst dye and WGA-488 respectively. Accordingly, aggregates were defined as RBCs/mo-DCs (white arrows), RBCs/HLMEC (yellow arrows), and RBCs/mo-DCs/HLMEC (pink arrows). (C) Quantification of cell aggregation calculated by imaging analysis software (left two panels). Several controls were used to access the ability of cell aggregation as indicated. Flow cytometric analysis of the integrin β1 expression on RBCs (middle panel). Integrin β1 on RBCs treated by LPS increased significantly compared to untreated control (graph bar panel, right side of flow cytometry picture). The α4β1 peptide inhibitor (10 µM) or Natalizmab (10 μg/ml) blocked cell-cell aggregation of RBCs/mo-DCs in a concentration-dependent manner while peptide control or Methylprednisolone alone had no effect on cell aggregation (Bottom right panel). All data were representative of mean ± SD, with at least three biological replicates. * p < 0.05, *** p < 0.001.
α2β1 Integrin Inhibitors, supplied by ShangPharma corp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/α2β1 integrin inhibitors/product/ShangPharma corp
Average 90 stars, based on 1 article reviews
α2β1 integrin inhibitors - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
integrin signaling inhibitors pf-00562271  (Cayman Chemical)
90
Cayman Chemical integrin signaling inhibitors pf-00562271
(A) Images of RBCs/mo-DCs aggregates captured by Keyence fluorescence microscope. RBCs and mo-DCs were pre-labeled with WGA-555 and Hoechst dye, respectively. Top panels show medium control; middle panels show LPS treated RBCs group (LPS 50 μg/ml for 24 h); bottom panels show the RBCs/mo-DCs group with RBC pretreated with 10 µM of the cyclic peptide inhibitor of <t>integrin</t> <t>α4β1.</t> White arrows pointed RBCs/mo-DCs aggregates. (B) The imaging strategy to distinguish cell aggregation with the corresponding three cell types in cell suspension. RBCs, mo-DCs, and HLMVEC were pre-labeled with WGA-555, Hoechst dye and WGA-488 respectively. Accordingly, aggregates were defined as RBCs/mo-DCs (white arrows), RBCs/HLMEC (yellow arrows), and RBCs/mo-DCs/HLMEC (pink arrows). (C) Quantification of cell aggregation calculated by imaging analysis software (left two panels). Several controls were used to access the ability of cell aggregation as indicated. Flow cytometric analysis of the integrin β1 expression on RBCs (middle panel). Integrin β1 on RBCs treated by LPS increased significantly compared to untreated control (graph bar panel, right side of flow cytometry picture). The α4β1 peptide inhibitor (10 µM) or Natalizmab (10 μg/ml) blocked cell-cell aggregation of RBCs/mo-DCs in a concentration-dependent manner while peptide control or Methylprednisolone alone had no effect on cell aggregation (Bottom right panel). All data were representative of mean ± SD, with at least three biological replicates. * p < 0.05, *** p < 0.001.
Integrin Signaling Inhibitors Pf 00562271, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/integrin signaling inhibitors pf-00562271/product/Cayman Chemical
Average 90 stars, based on 1 article reviews
integrin signaling inhibitors pf-00562271 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
av-integrin inhibitor crgdfv  (Bachem)
90
Bachem av-integrin inhibitor crgdfv
(A) Images of RBCs/mo-DCs aggregates captured by Keyence fluorescence microscope. RBCs and mo-DCs were pre-labeled with WGA-555 and Hoechst dye, respectively. Top panels show medium control; middle panels show LPS treated RBCs group (LPS 50 μg/ml for 24 h); bottom panels show the RBCs/mo-DCs group with RBC pretreated with 10 µM of the cyclic peptide inhibitor of <t>integrin</t> <t>α4β1.</t> White arrows pointed RBCs/mo-DCs aggregates. (B) The imaging strategy to distinguish cell aggregation with the corresponding three cell types in cell suspension. RBCs, mo-DCs, and HLMVEC were pre-labeled with WGA-555, Hoechst dye and WGA-488 respectively. Accordingly, aggregates were defined as RBCs/mo-DCs (white arrows), RBCs/HLMEC (yellow arrows), and RBCs/mo-DCs/HLMEC (pink arrows). (C) Quantification of cell aggregation calculated by imaging analysis software (left two panels). Several controls were used to access the ability of cell aggregation as indicated. Flow cytometric analysis of the integrin β1 expression on RBCs (middle panel). Integrin β1 on RBCs treated by LPS increased significantly compared to untreated control (graph bar panel, right side of flow cytometry picture). The α4β1 peptide inhibitor (10 µM) or Natalizmab (10 μg/ml) blocked cell-cell aggregation of RBCs/mo-DCs in a concentration-dependent manner while peptide control or Methylprednisolone alone had no effect on cell aggregation (Bottom right panel). All data were representative of mean ± SD, with at least three biological replicates. * p < 0.05, *** p < 0.001.
Av Integrin Inhibitor Crgdfv, supplied by Bachem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/av-integrin inhibitor crgdfv/product/Bachem
Average 90 stars, based on 1 article reviews
av-integrin inhibitor crgdfv - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


(A) Images of RBCs/mo-DCs aggregates captured by Keyence fluorescence microscope. RBCs and mo-DCs were pre-labeled with WGA-555 and Hoechst dye, respectively. Top panels show medium control; middle panels show LPS treated RBCs group (LPS 50 μg/ml for 24 h); bottom panels show the RBCs/mo-DCs group with RBC pretreated with 10 µM of the cyclic peptide inhibitor of integrin α4β1. White arrows pointed RBCs/mo-DCs aggregates. (B) The imaging strategy to distinguish cell aggregation with the corresponding three cell types in cell suspension. RBCs, mo-DCs, and HLMVEC were pre-labeled with WGA-555, Hoechst dye and WGA-488 respectively. Accordingly, aggregates were defined as RBCs/mo-DCs (white arrows), RBCs/HLMEC (yellow arrows), and RBCs/mo-DCs/HLMEC (pink arrows). (C) Quantification of cell aggregation calculated by imaging analysis software (left two panels). Several controls were used to access the ability of cell aggregation as indicated. Flow cytometric analysis of the integrin β1 expression on RBCs (middle panel). Integrin β1 on RBCs treated by LPS increased significantly compared to untreated control (graph bar panel, right side of flow cytometry picture). The α4β1 peptide inhibitor (10 µM) or Natalizmab (10 μg/ml) blocked cell-cell aggregation of RBCs/mo-DCs in a concentration-dependent manner while peptide control or Methylprednisolone alone had no effect on cell aggregation (Bottom right panel). All data were representative of mean ± SD, with at least three biological replicates. * p < 0.05, *** p < 0.001.

Journal: Frontiers in Pharmacology

Article Title: Integrin α4β1/VCAM-1 Interaction Evokes Dynamic Cell Aggregation Between Immune Cells and Human Lung Microvascular Endothelial Cells at Infectious Hemolysis

doi: 10.3389/fphar.2021.653143

Figure Lengend Snippet: (A) Images of RBCs/mo-DCs aggregates captured by Keyence fluorescence microscope. RBCs and mo-DCs were pre-labeled with WGA-555 and Hoechst dye, respectively. Top panels show medium control; middle panels show LPS treated RBCs group (LPS 50 μg/ml for 24 h); bottom panels show the RBCs/mo-DCs group with RBC pretreated with 10 µM of the cyclic peptide inhibitor of integrin α4β1. White arrows pointed RBCs/mo-DCs aggregates. (B) The imaging strategy to distinguish cell aggregation with the corresponding three cell types in cell suspension. RBCs, mo-DCs, and HLMVEC were pre-labeled with WGA-555, Hoechst dye and WGA-488 respectively. Accordingly, aggregates were defined as RBCs/mo-DCs (white arrows), RBCs/HLMEC (yellow arrows), and RBCs/mo-DCs/HLMEC (pink arrows). (C) Quantification of cell aggregation calculated by imaging analysis software (left two panels). Several controls were used to access the ability of cell aggregation as indicated. Flow cytometric analysis of the integrin β1 expression on RBCs (middle panel). Integrin β1 on RBCs treated by LPS increased significantly compared to untreated control (graph bar panel, right side of flow cytometry picture). The α4β1 peptide inhibitor (10 µM) or Natalizmab (10 μg/ml) blocked cell-cell aggregation of RBCs/mo-DCs in a concentration-dependent manner while peptide control or Methylprednisolone alone had no effect on cell aggregation (Bottom right panel). All data were representative of mean ± SD, with at least three biological replicates. * p < 0.05, *** p < 0.001.

Article Snippet: The cyclic peptide inhibitor of integrin α4β1 (azide modified peptide: MePhe-Leu-Asp-Val-Aib-Lys) ( ) control peptides (cyclic MePhe-Ala-Ala-Ala-Aib-Lys), and peptide drug conjugates (PDC), cyclic peptide inhibitor of integrin α4β1 conjugated methylprednisolone (α4β1/Methrol), and control peptide/methrol were synthesized using solid-supported chemistry by InnoPep Inc (San Diego, CA, United States).

Techniques: Fluorescence, Microscopy, Labeling, Control, Imaging, Suspension, Software, Expressing, Flow Cytometry, Concentration Assay

(A) LPS pretreated RBCs induced cell-cell aggregation on RBCs/mo-DCs, RBCs/HLMVEC, and RBCs/mo-DCS/HLMVEC (* p < 0.05 vs. untreated groups). Such effects were blocked by α4β1/Methrol (# p < 0.05). (B) LPS or L-sup enhanced mo-DCs migration (* p < 0.05, ## p < 0.01 vs. C-sup; * p < 0.05, L-sup vs. LPS alone) which was attenuated by α4β1/Methrol (* p < 0.01 vs. L-sup). (C) α4β1/Methrol decreased L-sup induced mo-DCs migration in a concentration-dependent manner [* p < 0.05 vs. peptide drug conjugate (PDC control)]. Data were representative of mean ± SD of three experiments. (D) GILZ-expressing mo-DCs analyzed by flow cytometry (dark color: PDC control; light black color: 10 µM α1β4/Methrol treatment for 24 h). (E) MFI values of GILZ-expressing mo-DCs quantitated by flow cytometry. α4β1/Methrol significantly increased the number of mo-DCs expressing GILZ as compared to PDC control (* p < 0.05).

Journal: Frontiers in Pharmacology

Article Title: Integrin α4β1/VCAM-1 Interaction Evokes Dynamic Cell Aggregation Between Immune Cells and Human Lung Microvascular Endothelial Cells at Infectious Hemolysis

doi: 10.3389/fphar.2021.653143

Figure Lengend Snippet: (A) LPS pretreated RBCs induced cell-cell aggregation on RBCs/mo-DCs, RBCs/HLMVEC, and RBCs/mo-DCS/HLMVEC (* p < 0.05 vs. untreated groups). Such effects were blocked by α4β1/Methrol (# p < 0.05). (B) LPS or L-sup enhanced mo-DCs migration (* p < 0.05, ## p < 0.01 vs. C-sup; * p < 0.05, L-sup vs. LPS alone) which was attenuated by α4β1/Methrol (* p < 0.01 vs. L-sup). (C) α4β1/Methrol decreased L-sup induced mo-DCs migration in a concentration-dependent manner [* p < 0.05 vs. peptide drug conjugate (PDC control)]. Data were representative of mean ± SD of three experiments. (D) GILZ-expressing mo-DCs analyzed by flow cytometry (dark color: PDC control; light black color: 10 µM α1β4/Methrol treatment for 24 h). (E) MFI values of GILZ-expressing mo-DCs quantitated by flow cytometry. α4β1/Methrol significantly increased the number of mo-DCs expressing GILZ as compared to PDC control (* p < 0.05).

Article Snippet: The cyclic peptide inhibitor of integrin α4β1 (azide modified peptide: MePhe-Leu-Asp-Val-Aib-Lys) ( ) control peptides (cyclic MePhe-Ala-Ala-Ala-Aib-Lys), and peptide drug conjugates (PDC), cyclic peptide inhibitor of integrin α4β1 conjugated methylprednisolone (α4β1/Methrol), and control peptide/methrol were synthesized using solid-supported chemistry by InnoPep Inc (San Diego, CA, United States).

Techniques: Migration, Concentration Assay, Control, Expressing, Flow Cytometry

Schematic diagram of the α4β1/Methrol reversing dendritic cell dysfunction in LPS-induced hemolysis. LPS-induced hemolysis resulted in an increase of integrin α4β1 expression on RBCs that subsequently mediated cell-cell aggregation, released cytokines/chemokines and evoked immune cell responses. LPS increased integrin α4β1 expression to facilitate cell-cell interaction of RBCs/mo-DCs, RBCs/HLMVEC, and RBCs/mo-DCs/HLMVEC. Cell aggregation of RBCs and mo-DCs further enhanced cytokines release and activation of NF-kB pathway in immune T cells. Chemokines/cytokines induced mo-DCs migration to HLMVEC. α4β1/VCAM-1 is an interconnective molecule for RBCs, mo-DCs, and HLMVEC aggregation at inflamed site. α4β1/Methrol blocked cell aggregation, decreases cell migration, protected the RBCs from hemolysis caused by LPS, as well as upregulated GILZ expression culminating in reversing the dysfunction of the immune cells, in particular dendritic cells.

Journal: Frontiers in Pharmacology

Article Title: Integrin α4β1/VCAM-1 Interaction Evokes Dynamic Cell Aggregation Between Immune Cells and Human Lung Microvascular Endothelial Cells at Infectious Hemolysis

doi: 10.3389/fphar.2021.653143

Figure Lengend Snippet: Schematic diagram of the α4β1/Methrol reversing dendritic cell dysfunction in LPS-induced hemolysis. LPS-induced hemolysis resulted in an increase of integrin α4β1 expression on RBCs that subsequently mediated cell-cell aggregation, released cytokines/chemokines and evoked immune cell responses. LPS increased integrin α4β1 expression to facilitate cell-cell interaction of RBCs/mo-DCs, RBCs/HLMVEC, and RBCs/mo-DCs/HLMVEC. Cell aggregation of RBCs and mo-DCs further enhanced cytokines release and activation of NF-kB pathway in immune T cells. Chemokines/cytokines induced mo-DCs migration to HLMVEC. α4β1/VCAM-1 is an interconnective molecule for RBCs, mo-DCs, and HLMVEC aggregation at inflamed site. α4β1/Methrol blocked cell aggregation, decreases cell migration, protected the RBCs from hemolysis caused by LPS, as well as upregulated GILZ expression culminating in reversing the dysfunction of the immune cells, in particular dendritic cells.

Article Snippet: The cyclic peptide inhibitor of integrin α4β1 (azide modified peptide: MePhe-Leu-Asp-Val-Aib-Lys) ( ) control peptides (cyclic MePhe-Ala-Ala-Ala-Aib-Lys), and peptide drug conjugates (PDC), cyclic peptide inhibitor of integrin α4β1 conjugated methylprednisolone (α4β1/Methrol), and control peptide/methrol were synthesized using solid-supported chemistry by InnoPep Inc (San Diego, CA, United States).

Techniques: Expressing, Activation Assay, Migration